Peer Review History

Original SubmissionJuly 1, 2025
Decision Letter - Nejat Mahdieh, Editor

-->PONE-D-25-35418-->-->Complete Molecular Spectrum of β-Globin Gene Mutations via Direct Sequencing Identifies Seven Novel Variants in β-Thalassemia Major-->-->PLOS ONE

Dear Dr. Othman,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 30 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Nejat Mahdieh

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its supporting information files.]

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

3. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 

Additional Editor Comments (if provided):

Reviewer #1:

Reviewer #2:

Reviewer #3:

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->2. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: The author should indicate the scoring system used for pathogenicity classification. The ACMG 2015 guideline is the most widely used one in the field. Terms such as "benign mutations" do not conform to current, standard terminology. Novel variants should be reported according to standard terminology so they can be checked in related databases. For example, "NM number, nucleotide change" or "genome version, chromosome position."

Reviewer #2: This is a highly relevant and clinically important study. The use of full-gene sequencing has successfully uncovered a significant number of novel variants, providing a valuable update to the mutational spectrum of β-thalassemia in the Kurdish population of Iraq. The findings have direct implications for improving local genetic diagnostics and counselling. The manuscript is generally well-structured, but several key issues need to be addressed to strengthen the validity and clarity of the conclusions:

1. Methods: Mentioning the ACMG/AMP guidelines is good. Briefly state which specific criteria (e.g., PVS1, PM2) were used to classify the novel variants as pathogenic/likely pathogenic.

2.Results: The study describes finding many mutations but does not clearly report the actual genotypes of the patients. How many were compound heterozygous? How many were homozygous? For instance, which specific combinations of the pathogenic mutations were found in the transfusion-dependent patients? Please add a table or a summary in the Results section. This directly links your molecular findings to the clinical presentation (Transfusion-Dependent Thalassemia).

3. The article requires proofreading and structural revision (e.g., concertation in line 127 and some inconsistencies in font size).

Reviewer #3: The article provides a comprehensive overview of β-thalassemia, including genetic background, clinical classification, prevalence, and regional context (particularly Iraq and the Kurdish population). It is well-structured and demonstrates a clear rationale for the study. However, a few points need improvement:

The background is lengthy and sometimes repetitive. Condensing these parts would make it more focused.

Some sentences are overly long or contain minor grammatical issues (e.g., “several studies have been partially addressed…” should be “several studies have partially addressed…”). Editing for readability would improve impact.

Ensure consistency in formatting (spacing around years, punctuation). Some references (e.g., “(Huang et al., 2022)..”) have typographical errors.

Some sentences in the method section are long or awkwardly phrased. For example:

“Informed consent were obtained…” → should be “Informed consent was obtained…”

“concertation and purity” → should be “concentration and purity.”

Minor inconsistencies (spacing, capitalization, punctuation in citations).

The table footnotes should be expanded to provide complete explanations of all abbreviations used.

It would be better to include sequencing chromatogram figures of the newly identified mutations and to provide more detailed bioinformatic analyses regarding their pathogenicity.

In the table, references should be cited for the mutations that are reported as pathogenic.

**********

-->6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .-->

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes:  Mahdieh Soveizi

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

We sincerely thank the reviewer for their meticulous evaluation and insightful comments, which have significantly strengthened the clarity, coherence, and scientific rigor of the manuscript. All revisions made in response to the reviewers’ suggestions are clearly highlighted in yellow in the Revised Manuscript with Track Changes.

Journal requirements:

Thank you for your guidance and for the helpful reminder concerning the journal’s requirements. We truly appreciate the editorial board’s efforts and support.

Comment 1: PLOS ONE's style requirements, including those for file naming and the style templates.

Answer: We revised the manuscript and ensured that it fully complied with PLOS ONE's style requirements, including the file naming conventions and following the PLOS ONE style templates guidelines. Additionally, all references are now fully compliant with the Vancouver (ICMJE) format used in biomedical journals.

Comment 2: Data Availability Statement.

Answer: We have confirmed that our submission contains all raw data required to replicate the results of our study, and the Data Availability Statement accurately reflects this.

Comment 3: Data sharing plan.

Answer: We reviewed our data sharing plan and ensured that all required data are available in accordance with PLOS ONE’s open data policy. Our Data Availability Statement has been updated accordingly. We appreciate your guidance on this matter.

Comment 4: Recommendation to cite specific previously published works.

Answer: We carefully reviewed the ACMG/AMP guidelines recommended by the reviewers and evaluated their relevance to our study. The appropriate works have been cited in the methodology section, and we are grateful for the constructive suggestions provided.

Response to Reviewers' Comments:

Reviewer#1:

Thank you very much for your insightful and constructive comments. We appreciate your suggestion regarding the pathogenicity classification system. In response, we have now clearly indicated that the ACMG (2015) guideline was used for variant interpretation, as it represents the current standard in the field. We have also revised the manuscript to replace non-standard terms such as “benign mutations” with the appropriate terminology recommended by ACMG/AMP. Furthermore, we have updated the reporting of novel variants to follow standard nomenclature, including NM numbers, nucleotide changes, and chromosomal position to ensure clarity and facilitate database verification.

Reviewer#2:

We sincerely thank the Reviewer for his/her thoughtful and encouraging comments on our manuscript. We greatly appreciate the recognition of the clinical relevance and contribution of our study to the understanding of β-thalassemia in the Kurdish population of Iraq.

1. Methods: Inclusion of the ACMG/AMP guidelines.

In response to your suggestion, we have now specified the exact criteria (e.g., PVS1, PM2, PP3, BS1) applied to classify the novel variants as pathogenic or likely pathogenic. This information has been added to the Methods section for greater transparency and clarity.

2. Results:

We appreciate your valuable suggestion to present the genotype distribution and its clinical correlation. Accordingly, we have revised the Results section to include a new summary detailing the genotypes of the patients, including the numbers of homozygous and compound heterozygous cases. The summary also highlights the specific combinations of pathogenic mutations observed in transfusion-dependent patients, thereby strengthening the link between molecular findings and clinical presentation.

3. Proofreading and structure:

The manuscript has been thoroughly proofread and edited to correct typographical errors to ensure consistent formatting throughout the text, including uniform font size and style. We are grateful for your constructive feedback, which has significantly improved the clarity and overall quality of our manuscript.

Reviewer#3:

We sincerely thank the Reviewer for her thoughtful and constructive comments, as well as for recognizing the value, structure, and rationale of our study. We greatly appreciate the time and effort taken to review our manuscript in such detail.

1. Background:

We have carefully revised and condensed this section to improve focus and flow, ensuring that only the most relevant information is retained to support the study rationale.

2. Language and readability:

The entire manuscript has been thoroughly edited for grammar, clarity, and sentence structure. We have also ensured that formatting is consistent throughout the text, including spacing around years, punctuation, and citation styles, and typographical errors in the references. We have reviewed the entire sections to ensure grammatical accuracy and improved readability.

3. Tables and footnotes:

As suggested, we have expanded the table footnotes to include full explanations of all abbreviations used. Additionally, how the previously reported pathogenic mutations have been described and cross-referenced to the relevant databases and guidelines for clarity and proper attribution.

4. Figures of the sequencing chromatograms:

Thank you for this excellent suggestion. We have now included sequencing chromatogram figures of the newly identified mutations to visually support our findings. We are very grateful for your detailed and constructive feedback, which has greatly helped us improve the quality, precision, and presentation of our manuscript.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Nejat Mahdieh, Editor

Complete Molecular Spectrum of β-Globin Gene Mutations via Direct Sequencing Identifies Seven Novel Variants in β-Thalassemia Major

PONE-D-25-35418R1

Dear Dr. Othman,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Nejat Mahdieh

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #3: All comments have been addressed

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #3: Yes

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #3: Yes

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #3: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #3: Yes

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #3: The authors have carefully and satisfactorily responded to comments. The revised version demonstrates significant improvement in both structure and content. I find the manuscript ready for publication in its present form.

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .-->

Reviewer #3: Yes:  Mahdieh Soveizi

**********

Formally Accepted
Acceptance Letter - Nejat Mahdieh, Editor

PONE-D-25-35418R1

PLOS ONE

Dear Dr. Othman,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Nejat Mahdieh

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .